Of these, two patients were treated with a third-generation TKI: 1 achieved SD and the other achieved partial response (PR).<h4>Conclusions</h4>This integrated retrospective analysis suggests that third-generation EGFR-TKIs may provide disease control (PR/SD) and prolonged PFS in a subset of NSCLC patients harboring uncommon EGFR p.L747P or p.L747S mutations, particularly those with co-existing sensitizing mutations or central nervous system metastases (CNS). Here, EGFR is linked to non-small cell lung carcinoma.